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Transcatheter aortic valve replacement 
(TAVR) has become an established treatment op-
tion for severe aortic valve stenosis. Given this 
situation, leaflet thrombosis of prosthesis after 
TAVR has been raised as a persisting concern, as it 
might cause systemic embolism or valve failure [1]. 
A prior report showed the relationship between 
leaflet thrombosis on enhanced computed tomog-
raphy and elevated D-dimer level [2], which is 
a product of fibrinolysis and is used as a sensi-
tive marker of intravascular thrombus [3]. An 
antiplatelet agent is used in the current standard 
antithrombotic regimen after TAVR; however, 
some recent reports suggest that patients treated 
with anticoagulant therapy after TAVR were at 
lower risk of leaflet thrombosis than those treated 
without anticoagulant therapy [4, 5]. The purpose 
of this study was to compare the D-dimer levels 
during the perioperative period of TAVR between 
patients with and without anticoagulant therapy.
From among 114 consecutive patients who 
received TAVR between April 2016 and June 2019 
at Nagoya University Hospital, subjects were iden-
tified with available perioperative D-dimer levels 
(more than once within 7 days after TAVR). Pa-
tients were excluded if their postoperative D-dimer 
levels were not available (n = 19), anticoagulant 
therapy was changed to antiplatelet therapy or vice 
versa within 7 days (n = 2), antithrombotic therapy 
was not started within 5 days of TAVR (n = 5), or 
the baseline D-dimer level before TAVR was ex-
tremely high (D-dimer level > 10 IU/mL; n = 1). 
Finally, 87 patients were analyzed in this study. 
The highest D-dimer levels were defined within 
7 days after TAVR as “peak D-dimer” and the 
D-dimer level before TAVR as “baseline D-dimer”. 
DD-dimer was also calculated with peak and base-
line D-dimer levels.
Categorical variables are presented as num-
bers and percentages, and continuous variables are 
presented as mean ± standard deviation or median 
(interquartile range). To compare the categorical 
variables, c2 or the Fisher exact test was used. 
Continuous variables were compared using a t test 
or the Mann-Whitney test. P values < 0.05 were 
considered to indicate statistical significance. All 
statistical analyses were performed using SPSS 
version 26.0 (SPSS, Chicago, Illinois).
Patient characteristics are shown in Table 1. 
Of the 87 patients, 21 received anticoagulants 
(2 received warfarin; 12, direct oral anticoagulants 
[DOAC]; and 7, both DOAC and single antiplate-
let agents). Seventeen patients received antico-
agulants for atrial fibrillation at baseline, and the 
other 4 patients started taking anticoagulants after 
TAVR. Sixty-six patients received only antiplatelet 
agents without anticoagulants (11 received dual 
and 55 received single antiplatelet therapy). The 
patients treated with anticoagulant therapy had 
atrial fibrillation more frequently.
The perioperative D-dimer levels are shown in 
Table 1. The peak D-dimer level was significantly 
lower in the patients treated with anticoagulants 
than in those treated without anticoagulants (2.38 
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Age [years] 84 ± 4 84 ± 5 0.51
Male 7 (33%) 22 (33%) 1.00
Height [cm] 148 (146–160) 147 (143–153) 0.20
Body weight [kg] 48 (42–54) 48 (41–61) 0.68
Body mass index 21.8 (19.2–26.6) 22.5 (18.9–26.7) 0.17
Hypertension 16 (76%) 50 (76%) 0.97
Dyslipidemia 14 (67%) 38 (58%) 0.46
Diabetes mellitus 7 (33%) 23 (35%) 0.90
eGFR < 60 mL/min/1.73 m2 12 (57%) 48 (73%) 0.18
Atrial fibrillation 17 (81%) 2 (3%) < 0.001
Extracardiac arteriopathy 4 (19%) 9 (14%) 0.38
Active cancer 2 (10%) 0 (0%) 0.06
Previous cardiac surgery 3 (15%) 4 (6%) 0.22
STS score 5.9 (5.0–8.9) 5.6 (4.4–7.6) 0.41
Echocardiography
Left ventricular ejection fraction [%] 66.5 (62.0–75.0) 64.5 (59.0–71.9) 0.34
Mean pressure gradient [mmHg] 43.3 (38.7–51.2) 43.5 (36.0–62.1) 0.78
Aortic valve area [cm2] 0.57 ± 0.15 0.60 ± 0.18 0.38
Computed tomography
Annulus area [cm2] 420.9 ± 63.9 410.7 ± 76.8 0.59
Annulus perimeter [mm] 73.9 ± 5.6 73.0 ± 6.2 0.62
Mean sinus of Valsalva diameter [mm] 29.6 ± 3.1 29.5 ± 3.1 0.95
Procedural characteristics
Approach site: 0.55
Transfemoral 20 (95%) 61 (92%)
Non-transfemoral 1 (5%) 5 (8%)
Prosthesis type: 0.79
SAPIEN XT/3 14 (67%) 46 (70%)
Evolut R/Pro 7 (33%) 20 (30%)
Antithrombotic therapy:
Warfarin only 2 0
DOAC only 12 0




Baseline D-dimer level [IU/mL] 0.50 (0.50–0.65)* 1.10 (0.64–1.95)* 0.003
Peak D-dimer level [IU/mL] 2.38 (1.74–4.29) 5.15 (2.64–8.51) 0.001
DD-dimer 1.56 (0.83–2.48)* 5.05 (2.10–7.76)* < 0.001
eGFR — estimated glomerular filtration rate; STS — Society of Thoracic Surgeons; DOAC — direct oral anticoagulant; DAPT — dual antiplate-
let therapy; SAPT — single antiplatelet therapy; DD-dimer — peak minus baseline D-dimer levels; *Baseline D-dimer levels were available in 
16 patients with anticoagulant and 46 patients without anticoagulant, therefore, DD-dimer was calculated in those patients
IU/mL [1.74–4.29 IU/mL] vs. 5.15 IU/mL [2.64–
–8.51 IU/mL]; p = 0.001). The baseline D-dimer 
(0.50 IU/mL [0.50–0.65 IU/mL] vs. 1.10 IU/mL 
[0.64–1.95 IU/mL]; p = 0.003) and D-dimer levels 
(1.56 IU/mL [0.83–2.48 IU/mL] vs. 5.05 IU/mL 
[2.10–7.76 IU/mL]; p < 0.001) were significantly 
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lower in the patients with, than in those without 
anticoagulant therapy.
Preliminary data showed that the baseline, 
peak, and ΔD-dimer levels were significantly lower 
in patients with anticoagulant therapy. Recent 
reports suggest the effectiveness of anticoagulant 
therapy for prevention and treatment of leaflet 
thrombosis after TAVR [4, 5], and the present data 
may support these results. D-dimer levels could 
be affected by various factors, and suppression of 
the increase in D-dimer level might not directly 
demonstrate the effectiveness of anticoagulant 
therapy. Prior reports have shown that D-dimer 
levels decreased in patients with atrial fibrillation 
after initiation of DOAC therapy [6], and antico-
agulant therapy might suppress the coagulation 
reaction and formation of leaflet thrombosis of pros-
thesis after TAVR. However, the effectiveness of 
a prevention for leaflet thrombosis does not mean 
it is the optimal therapy for patients undergoing 
TAVR [7, 8] because the balance between safety 
and efficacy for the various issues should be con-
sidered in clinical practice. Further investigations 
are required to address the optimal antithrombotic 
regimen in patients undergoing TAVR.
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